Accession Number:

ADA586646

Title:

Sensitivity of Breast Cancer Stem Cells to TRA-8 Anti-DR5 Monoclonal Antibody

Descriptive Note:

Annual summary rept. 15 Jan 2013-31 Jul 2013

Corporate Author:

ALABAMA UNIV IN BIRMINGHAM

Personal Author(s):

Report Date:

2013-08-01

Pagination or Media Count:

68.0

Abstract:

Basal-like breast cancers BLBCs generally become resistant to cytotoxic agents and resistance has been attributed to the presence of tumor initiating cancer stem cells CSCs. Furthermore, LRP6Wnt appears to play a crucial role in BLBC and CSC progression, and may represent an excellent therapeutic target. We have previously described that TRA-8, a monoclonal antibody specific to death receptor 5, kills both the CSCs and non-CSC population of BLBCs. This study examined two questions whether niclosamide an FDA approved antihelminthic, that inhibits Wnt -catenin signaling is cytotoxic to BLBCs and its CSC population and whether niclosamide in combination with TRA-8 produces synergistic cytotoxicity. We characterized non-adherent ALDH enriched NAAE cells as a CSC enriched population from BLBC cell lines. Both Adherent and NAAE cells from 2LMP, SUM159, HCC1187, HCC1143 cell lines and patient pleural effusion samples showed that niclosamide inhibited Wnt -catenin pathway activation, down regulated LRP6, and decreased downstream -catenin signaling. The combination of TRA-8 and niclosamide showed additive to synergistic cytotoxicity and further reduced Wnt -catenin activity. In vivo studies also showed that intraperitoneal administration of niclosamide in combination with TRA-8 suppressed growth of established 2LMP orthotopic tumor xenografts. Treatment with niclosamide in combination with TRA-8 may be an effective therapy against BLBC.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE